Skip to content
Voxzogo(vosoritide)
Voxzogo (vosoritide) is a protein pharmaceutical. Vosoritide was first approved as Voxzogo on 2021-08-26. It is used to treat achondroplasia and dwarfism in the USA. It has been approved in Europe to treat achondroplasia. It is known to target atrial natriuretic peptide receptor 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
hereditary congenital and neonatal diseases and abnormalitiesD009358
endocrine system diseasesD004700
Trade Name
FDA
EMA
Voxzogo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vosoritide
Tradename
Company
Number
Date
Products
VOXZOGOBioMarin PharmaceuticalN-214938 RX2021-11-19
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
voxzogo 0.4mg voxzogo 0.56mg voxzogo 1.2mgNew Drug Application2021-12-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
achondroplasia—D000130Q77.4
dwarfism—D004392E34.31
Agency Specific
FDA
EMA
Expiration
Code
VOSORITIDE, VOXZOGO, BIOMARIN PHARM
2028-11-19ODE-387
2026-11-19NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Vosoritide, Voxzogo, Biomarin Pharm
99078342036-08-01DP
106465502036-08-01DPU-3256
81982422030-06-11DS, DPU-3256
RE482672030-05-20U-3256
ATC Codes
M: Musculo-skeletal system drugs
— M05: Drugs for treatment of bone diseases
— M05B: Drugs affecting bone structure and mineralization
— M05BX: Other drugs affecting bone structure and mineralization in atc
— M05BX07: Vosoritide
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AchondroplasiaD000130Q77.4152——8
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVOSORITIDE
INNvosoritide
Description
Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia.
Classification
Protein
Drug classpeptides: atrial natriuretic type substances
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1480724-61-5
RxCUI—
ChEMBL IDCHEMBL3707276
ChEBI ID—
PubChem CID—
DrugBankDB11928
UNII ID7SE5582Q2P (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
NPR2
NPR2
Organism
Homo sapiens
Gene name
NPR2
Gene synonyms
ANPRB
NCBI Gene ID
4882
Protein name
atrial natriuretic peptide receptor 2
Protein synonyms
ANP-B, ANPR-B, atrial natriuretic peptide B-type receptor, Atrial natriuretic peptide receptor type B, GC-B, guanylate cyclase 2B, Guanylate cyclase B, guanylyl cyclase B, natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B), NPR-B
Uniprot ID
Q9UQ50
Mouse ortholog
Npr2 (230103)
atrial natriuretic peptide receptor 2 (Q8CGA9)
Variants
Clinical Variant
No data
Financial
Voxzogo - BioMarin Pharmaceutical
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 89 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details